Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced the pricing of its previously announced underwritten public offering of 10m shares of its common stock at a price to the public of $4 per share for net proceeds of approximately $37,250,000.
NeurogesX, Inc. (Nasdaq:NGSX), today announced it submitted a supplemental new drug application (sNDA) to the FDA seeking to expand the label for Qutenza (capsaicin) 8% patch to include an indication for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN), also known as HIV-associated neuropathy (HIV-AN) and HIV-distal sensory polyneuropathy (HIV-DSP).
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the completion of enrollment and randomization of 86 patients with previously untreated non-small cell lung cancer (NSCLC) in a Phase 2 trial evaluating bavituximab in combination with carboplatin and paclitaxel. Interim Data is expected by the end of 2011. In addition, patient recruitment is ongoing in its second-line NSCLC trial evaluating docetaxel with bavituximab or placebo in up to 120 patients with previously treated locally advanced or metastatic NSCLC. Patient enrollment is expected to be completed early in the fourth quarter of 2011.
Alkermes, Inc. (NASDAQ: ALKS) announced that Alkermes shareholders have approved the merger of Alkermes and Elan Drug Technologies. Alkermes currently anticipates that the business combination will close on Sept. 16, 2011. Following the merger, Alkermes plc will be listed on the NASDAQ stock exchange under Alkermes current ticker symbol ALKS.
Exelixis, Inc. (Nasdaq: EXEL) yesterdaty announced that the pre-specified number of progression-free survival (PFS) events required for un-blinding of the data for the ongoing phase 3 pivotal trial of cabozantinib in patients with medullary thyroid cancer (MTC), known as the EXAM trial, has been reached. Final data analysis in preparation for un-blinding is underway, and the company expects to report top-line data early in the fourth quarter of 2011.